Motley Rice medical attorneys appointed to lead C.R. Bard hernia mesh litigation
Motley Rice medical attorneys Donald Migliori and Jonathan Orent have been appointed as co-lead counsel, liaison counsel and members of the Plaintiffs’ Steering Committee for litigation alleging harm caused by certain hernia mesh products manufactured by C.R. Bard and its subsidiary Davol, Inc.
Superior Court Presiding Justice Alice Gibney, who is overseeing the litigation coordinated in Rhode Island state court, announced the leadership appointments in an order filed on Nov. 8, 2017. Developments in the case come in addition to separate litigation in the state targeting Bard’s Composix® Kugel® mesh patches, and raise safety concerns about the company’s other hernia repair products, including Composix, Composix E/X, Ventrio, Ventrio ST, Ventralex, Ventralex ST, 3D Max, Perfix Plug, Marlex, and Bard Mesh.
Motley Rice is reviewing all hernia mesh manufactured by C.R. Bard made of Marlex polypropylene. If defective, the products can lead to severe complications, including hernia recurrence requiring additional surgeries, mesh migration, infection, adhesions and other injuries.
Both Don and Jonathan hold additional leadership positions involving allegedly defective hernia mesh, including Don serving as co-lead counsel for hernia mesh litigation In re Ethicon Physiomesh Flexible Composite Hernia Mesh Products Liability Litigation, and Jonathan being lead counsel for In re Atrium Medical Corp. C-QUR Mesh Products Liability Litigation. In addition, Don serves as co-lead plaintiffs' counsel and liaison counsel for federal multidistrict litigation regarding Composix Kugel Mesh, as well as being liaison counsel for the nearly 2,000 Composix Kugel Mesh lawsuits consolidated in Rhode Island state court. Motley Rice has also previously litigated against C.R. Bard in the transvaginal mesh litigation.
If you were implanted with hernia mesh and later developed symptoms, you may contact Donald Migliori and Jonathan Orent by email or call 1.800.768.4026.